[go: up one dir, main page]

PE20142367A1 - Formulaciones de imiquimod - Google Patents

Formulaciones de imiquimod

Info

Publication number
PE20142367A1
PE20142367A1 PE2014000347A PE2014000347A PE20142367A1 PE 20142367 A1 PE20142367 A1 PE 20142367A1 PE 2014000347 A PE2014000347 A PE 2014000347A PE 2014000347 A PE2014000347 A PE 2014000347A PE 20142367 A1 PE20142367 A1 PE 20142367A1
Authority
PE
Peru
Prior art keywords
acid
formulations
imiquimod formulations
alcohol
imiquimod
Prior art date
Application number
PE2014000347A
Other languages
English (en)
Inventor
Michael T Nordsiek
Sharon F Levy
James H Lee
James H Kulp
Kodumudi S Balaji
Tze-Chiang Meng
Jason J Wu
Valyn S Bahm
Robert Babilon
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142367(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of PE20142367A1 publication Critical patent/PE20142367A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A FORMULACIONES DE IMIQUIMOD QUE COMPRENDEN EXCIPIENTES TALES COMO ACIDOS GRASOS, ALCOHOL CETILICO, ALCOHOL ESTEARILICO, VASELINA BLANCA, GLICERINA, GOMA XANTANA, METILPARABENO, ENTRE OTROS, DONDE EL ACIDO GRASO ES ACIDO LINOLEICO, ESTEARICO, PALMITICO, ISOESTEARICO, ENTRE OTROS. DICHAS FORMULACIONES SON UTILES EN EL TRATAMIENTO DE LA QUERATOSIS ACTINICA
PE2014000347A 2008-12-19 2009-12-18 Formulaciones de imiquimod PE20142367A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13953608P 2008-12-19 2008-12-19
US14473109P 2009-01-14 2009-01-14
US20514509P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
PE20142367A1 true PE20142367A1 (es) 2015-01-10

Family

ID=42316709

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009001323A PE20100469A1 (es) 2008-12-19 2009-12-18 Formulaciones de imiquimod
PE2014000347A PE20142367A1 (es) 2008-12-19 2009-12-18 Formulaciones de imiquimod

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2009001323A PE20100469A1 (es) 2008-12-19 2009-12-18 Formulaciones de imiquimod

Country Status (28)

Country Link
US (13) US20110021555A1 (es)
EP (1) EP2378876B1 (es)
AR (1) AR074802A1 (es)
AU (1) AU2009335943A1 (es)
BR (1) BRPI0923164A2 (es)
CL (1) CL2009002183A1 (es)
CO (1) CO6400171A2 (es)
CR (1) CR20110338A (es)
CY (1) CY1121485T1 (es)
DK (1) DK2378876T3 (es)
DO (1) DOP2011000195A (es)
EA (1) EA201100984A1 (es)
ES (1) ES2720149T3 (es)
GE (1) GEP20146198B (es)
HR (1) HRP20190306T1 (es)
HU (1) HUE041944T2 (es)
IL (2) IL213628A (es)
LT (1) LT2378876T (es)
MX (2) MX2011001555A (es)
PA (1) PA8855101A1 (es)
PE (2) PE20100469A1 (es)
PL (1) PL2378876T3 (es)
PT (1) PT2378876T (es)
RS (1) RS58566B1 (es)
SI (1) SI2378876T1 (es)
SM (1) SMT201900195T1 (es)
TW (1) TWI442923B (es)
WO (1) WO2010080345A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030089A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Transgenic plants with enhanced growth characteristics
US20110030104A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
GEP20146198B (en) 2008-12-19 2014-11-25 Graceway Pharmaceuticals Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
BR112012000797A2 (pt) 2009-07-13 2016-08-09 Medicis Pharmaceutical Corp formulações de imiquimode de intensidade de dosagem inferior e regimes curtos de dosagem para tratamento de verrugas genitais e perianais
EP2584900B1 (en) * 2010-06-25 2019-01-02 Medicis Pharmaceutical Corporation Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
US9072876B2 (en) 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) * 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
BR112014013227A2 (pt) * 2011-11-30 2017-06-13 Merz Pharma Gmbh & Co Kgaa uso de álcoois peguilados no tratamento de queratose actínica
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
IL293871B1 (en) 2013-08-30 2025-10-01 Immunogen Inc Antibodies and assays for the detection of folate receptor 1
US9576445B2 (en) 2013-09-06 2017-02-21 Immersion Corp. Systems and methods for generating haptic effects associated with an envelope in audio signals
US9619980B2 (en) 2013-09-06 2017-04-11 Immersion Corporation Systems and methods for generating haptic effects associated with audio signals
US9711014B2 (en) 2013-09-06 2017-07-18 Immersion Corporation Systems and methods for generating haptic effects associated with transitions in audio signals
RU2696579C2 (ru) * 2013-10-08 2019-08-05 Иммьюноджен, Инк. Схемы применения иммуноконъюгата анти-folr1
EP3939593A1 (en) 2014-09-10 2022-01-19 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
JP7502863B2 (ja) * 2017-03-10 2024-06-19 エイティーエヌエックス エスピーブイ リミテッド ライアビリティ カンパニー 光線角化症を治療および／または予防する方法
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT610737A (es) 1955-11-18 1900-01-01
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (sv) 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
ATE304852T1 (de) 1999-01-08 2005-10-15 3M Innovative Properties Co Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
WO2002102377A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
WO2004080430A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods of improving skin quality
DK1450804T3 (da) * 2001-11-29 2009-01-05 3M Innovative Properties Co Farmaceutiske formulelringer, der omfatter et immunsvarmodificerende middel
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
JP2006523212A (ja) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー 皮膚病変の診断方法
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7521459B2 (en) * 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
US20090232755A1 (en) * 2003-07-28 2009-09-17 Leslie Baumann Combination therapies for treating photodamaged skin
JP2007504172A (ja) 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
EP1704142A4 (en) 2003-12-31 2008-08-20 Taigen Biotechnology Co Ltd PROTEASE INHIBITORS
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
WO2005110013A2 (en) * 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
US20070196452A1 (en) 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (zh) 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105028A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
EP1931624A1 (en) * 2005-08-31 2008-06-18 Serentis Limited Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with staphylococcus aureus
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US8703753B2 (en) * 2005-09-15 2014-04-22 Biomas Ltd. Use of tellurium compounds for the treatment of actinic keratosis
US20070081962A1 (en) 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
US9023863B2 (en) * 2006-07-14 2015-05-05 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
IL184563A (en) 2006-07-18 2014-07-31 Meda Ab Pharmaceutical foam formulations and their use
AU2007279376B2 (en) 2006-07-31 2012-09-06 Wirra Ip Pty Ltd Immune response modifier compositions and methods
EP2076260B1 (en) * 2006-09-15 2011-03-23 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
CN102898416A (zh) * 2006-09-26 2013-01-30 细胞基因公司 作为抗肿瘤剂的5-取代的喹唑酮衍生物
EP3176169A1 (en) * 2007-01-31 2017-06-07 Chongxi Yu Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
WO2008098232A1 (en) * 2007-02-08 2008-08-14 Graceway Pharmaceuticals, Llc Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
CA2679067A1 (en) * 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118765A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en) 2007-05-08 2008-11-20 The Brigham And Women's Hospital, Inc Methods and products for treating proliferative disorders
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en) 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en) * 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
BRPI0907191A2 (pt) * 2008-01-15 2015-07-14 Dow Pharmaceutical Sciences Solução, método para preparar uma solução, método para aumentar a penetração cutânea de imiquimod ou um análogo do mesmo
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
US20090246156A1 (en) * 2008-03-31 2009-10-01 Audrey Kunin Anti-acne sunscreen composition
JP2011516478A (ja) * 2008-04-03 2011-05-26 コグネイト ３，エルエルシー 免疫療法のための組成物および方法
JP2011518885A (ja) 2008-04-28 2011-06-30 ノバルティス アーゲー 医薬組成物における使用のためのナノ粒子
US20110077297A1 (en) 2008-05-30 2011-03-31 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
KR20110090892A (ko) 2008-10-31 2011-08-10 모베르그 데르마 아베 두 개 이상의 침투 증강제의 조합으로 구성되는 국소 조성물
GEP20146198B (en) 2008-12-19 2014-11-25 Graceway Pharmaceuticals Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BR112012000797A2 (pt) 2009-07-13 2016-08-09 Medicis Pharmaceutical Corp formulações de imiquimode de intensidade de dosagem inferior e regimes curtos de dosagem para tratamento de verrugas genitais e perianais
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US9072876B2 (en) * 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) * 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

Also Published As

Publication number Publication date
CO6400171A2 (es) 2012-03-15
EP2378876B1 (en) 2018-11-14
CR20110338A (es) 2011-11-10
US8299109B2 (en) 2012-10-30
US9370509B2 (en) 2016-06-21
US10238644B2 (en) 2019-03-26
IL255163A0 (en) 2017-12-31
TWI442923B (zh) 2014-07-01
US20110021555A1 (en) 2011-01-27
HRP20190306T1 (hr) 2019-05-03
PL2378876T3 (pl) 2019-06-28
IL255163B (en) 2019-01-31
BRPI0923164A2 (pt) 2016-01-26
US20110263636A1 (en) 2011-10-27
ES2720149T3 (es) 2019-07-18
US20160303111A1 (en) 2016-10-20
SI2378876T1 (sl) 2019-05-31
EP2378876A4 (en) 2012-12-05
US11318130B2 (en) 2022-05-03
US20130210855A1 (en) 2013-08-15
US20110263633A1 (en) 2011-10-27
IL213628A (en) 2017-11-30
US20110263637A1 (en) 2011-10-27
US20110257216A1 (en) 2011-10-20
US20110257219A1 (en) 2011-10-20
AU2009335943A1 (en) 2013-10-24
LT2378876T (lt) 2019-04-25
PA8855101A1 (es) 2010-07-27
DOP2011000195A (es) 2011-12-15
US20110263634A1 (en) 2011-10-27
GEP20146198B (en) 2014-11-25
AR074802A1 (es) 2011-02-16
US20200276182A1 (en) 2020-09-03
TW201040173A (en) 2010-11-16
HUE041944T2 (hu) 2019-06-28
MX2011001555A (es) 2011-04-14
CY1121485T1 (el) 2020-05-29
US20110257217A1 (en) 2011-10-20
MX346455B (es) 2017-03-21
US20110257218A1 (en) 2011-10-20
EA201100984A1 (ru) 2012-01-30
RS58566B1 (sr) 2019-05-31
EP2378876A1 (en) 2011-10-26
US8222270B2 (en) 2012-07-17
US20110263635A1 (en) 2011-10-27
SMT201900195T1 (it) 2019-05-10
PE20100469A1 (es) 2010-07-31
DK2378876T3 (en) 2019-03-11
WO2010080345A1 (en) 2010-07-15
PT2378876T (pt) 2019-03-01
CL2009002183A1 (es) 2011-01-07
US8236816B2 (en) 2012-08-07
IL213628A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
PE20142367A1 (es) Formulaciones de imiquimod
CL2019002477A1 (es) Producción de ácidos graso poliinsaturados de cadena larga en células vegetales. (divisional solicitud 201403402)
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
PE20080886A1 (es) Metodo para la produccion de semilla de maiz hibrido y composiciones producidas a partir del mismo
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
UA114615C2 (uk) Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
CO6420355A2 (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CO6541606A2 (es) Espiroindolinona- pirrolidinas
MY205872A (en) Pharmaceutical compositions comprising omega-3 fatty acids
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
GB2459809A (en) Fatty acid formulations and methods of use thereof
MX2012002089A (es) Composiciones alcoholicas que tienen un riesgo reducido de acetaldehidemia.
CO6390030A2 (es) Sellador de teta intramamario
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
EA201690854A1 (ru) Фармацевтические композиции с гидратирующим и смазывающим действием
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
PE20141068A1 (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico
BR112012012649A2 (pt) agente indutor de beta-defensina humana, formulação, e, usos de um agente indutor de beta-defensiva humana, e de pelo menos uma gordura ou óleo de um triglicerídeo de ácido graxo essencial ou de um derivado do mesmo.
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
AR061646A1 (es) Profarmacos de penem
CL2011001539A1 (es) Compuestos derivados de un acido graso poliinsaturado omega 3 u omega 6 y un ester de diol con actividad anti-inflamatoria y antibacteriana; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento del acne o la dermatitis seborreica.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed